ReviewDrug delivery2025
Metal nanoparticles in cancer theranostics: from synthesis to tumor microenvironment-responsive applications.
Review in Drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Camptothecin Nanoformulations: Recent Advances in Preparation, Bioactivities, and Clinical Perspectives.Annals of biomedical engineering · 2026Review
- Listening to Immunotherapy - Ultrasound and Photoacoustic Imaging Strategies to Guide and Enhance Cancer Treatments.Molecular imaging and biology · 2026Review
- Nanotechnology-enabled precision strategies for bladder cancer: from in vitro diagnostics to in vivo therapy.Journal of nanobiotechnology · 2026Review
- Precise Catalysis and Immune Activation: New Strategies for Tumor Immunotherapy with Cascade Nanozymes.International journal of nanomedicine · 2026Review
- Metal Nanoparticles as Sensitizers in Energy-Based Therapies for Lung Cancer: From Mechanistic Insights to Clinical Translation.International journal of nanomedicine · 2026Review
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer poses a major threat to human health, and conventional treatments (such as surgery, radiotherapy (RT), and chemotherapy) are often associated with significant toxic side effects, poor targeting, and drug resistance. In recent years, nanomedicine, an emerging interdisciplinary field, has provided novel strategies for cancer diagnosis and therapy by enabling precise drug delivery and multifunctional integration. Among various nanoplatforms, metal nanoparticles (MNPs) have become a research hotspot due to their unique physicochemical properties, including optical characteristics, catalytic activity, and surface modifiability. This article systematically explores the role of MNPs in cancer therapy. It first outlines their classification and synthesis strategies. Subsequently, it analyzes their innovative applications in tumor diagnosis, RT, chemotherapy, and immunotherapy. A key focus is placed on elucidating how MNPs exploit distinctive features of the tumor microenvironment - such as acidic pH, elevated reactive oxygen species (ROS) levels, and high glutathione (GSH) concentrations - to achieve responsive and targeted drug delivery. Finally, the main challenges currently faced in this field are analyzed. This review aims to provide theoretical guidance and technical references for the rational design and clinical translation of MNPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.